Our Recommendations
New Publications
- Recomendaciones provisionales sobre el uso de la vacuna CanSinoBIO Ad5-nCoV-S [recombinante] (Convidecia™) contra la COVID-19: orientaciones provisionales, primera publicación: 19 de mayo de 2022 (2022)
- Good practice statement on the use of variant-containing COVID-19 vaccines (2022)
- WHO Science in 5 Episode #78 - mRNA technologies (2022)
- Interim recommendations for use of the Valneva VLA2001 vaccine against COVID 19: interim guidance (2022)
- Interim recommendations for use of the CanSinoBIO Ad5-nCoV-S [recombinant] vaccine (Convidecia™) against COVID-19: interim guidance, first issued 19 May 2022 (2022)
Filter
132
Featured
Recommendations
24
Language
Document type
Guidelines
44
Fact sheets
43
Studies & Reports
14
Resource Platforms
11
Manuals
7
Infographics
5
Situation Updates
4
Videos
3
Training Material
1
Countries / Regions
Germany
16
Brazil
8
Russia
8
West and Central Africa
6
East and Southern Africa
6
Argentina
6
India
6
Mozambique
3
Africa
3
Latin America and the Carribbean
2
Middle East and North Africa
2
Western and Central Europe
2
South Sudan
2
Turkey
1
Kazakhstan
1
Global
1
Haiti
1
Guinea-Bissau
1
France
1
United Kingdom
1
Portugal
1
Spain
1
South Korea
1
Belarus
1
Vietnam
1
Angola
1
Authors & Publishers
Publication Years
Category
COVID-19
52
Guidelines
11
Information, Education and Communication (IEC)
7
Studies & Reports
4
x MEDBOX Issue Brief & Annual Reports x
2
Women & Child Health
2
Countries
1
Policies
1
Immunization
1
Toolboxes
Vaxzevria (Astra Zeneca)
26
Research & Pipeline
26
Biontech/Pfizer Comirnaty
23
Inactivated COVID-19 Vaccines
18
mRna Vaccines general
14
Vector-based Vacines General
14
Moderna
13
Johnson & Johnson
8
Covaxin
6
Sputnik V
3
COVID-19 vaccine tracker and landscape
recommended
The COVID-19 vaccine tracker and landscape compiles detailed information of each COVID-19 vaccine candidate in development by closely monitoring their progress through the pipeline.
The COVID-19 vaccine tracker:
Provides summary tables of COVID-19 vaccine candidates in both clinical and pre-...
These WHO interim recommendations on the use of the Pfizer – BioNTech BNT162b2 vaccine against Covid-19 were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document referenced below.
fir...
orientations provisoires, première publication : 8 janvier 2021, mise à jour : 15 juin 2021, mise à jour : 19 novembre 2021, mise à jour : 21 janvier 2022
These WHO interim recommendations on the use of the Astra Zeneca – Oxford University AZD1222 vaccine against Covid-19 were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document referenc...
6 June 2022
These WHO interim recommendations on the use of the Janssen Ad26.COV2.S (COVID-19) vaccine were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document referenced below.
Th...
Interim Guidance October 2022. This addendum addresses some of the methodological aspects of VE evaluations that have been learned during the past year, as well as those that have become relevant in the current epidemiological setting of the COVID-19 pandemic. For some of the COVID-19 vaccine method...
Interim recommendations for use of the inactivated COVID-19 vaccine, CoronaVac, developed by Sinovac
These WHO interim recommendations for use of the Sinovac-CoronaVac were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document and annexes referenced below.
This document has been updat...
Bisher hat die STIKO empfohlen, dass alle im Ausland mit einem nicht in der EU zugelassenen Impfstoff geimpften Personen eine erneute Impfserie mit einem in der EU zugelassenen Impfstoff erhalten sollen. Ziel der im Epidemiologischen Bulletin 13/2022 veröffentlichten aktualisierten COVID-19-Impfemp...
orientaciones provisionales, primera publicación: 24 de mayo de 2021, actualización: 21 de octubre de 2021, actualización: 15 de marzo de 2022
Временное руководство (Первый выпуск 24 мая 2021 г., Обновлено 21 октября 2021 г., Обновлено 15 марта 2022 г.
These WHO interim recommendations for use of the BBV152 COVAXIN vaccine were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document and annexes referenced below.
This document has been ...
This chronology of facts has challenged public health systems worldwide and regulatory bodies are no exception. Regulatory authorities with mechanisms in place to authorize the use of investigational products had to development guidelines and procedures, create task forces and alliances to maximize ...
These WHO interim recommendations for use of the COVID-19 vaccine BIBP produced by Sinopharm were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document and annexes referenced below.
Th...
27 September 2022
These WHO interim recommendations for use of the Novavax NVX-CoV2373 vaccine were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document and annexes referenced below.
Comirnaty® 10 μg und 30 μg von BioNTech / Pfizer und Spikevax® von Moderna
Stand 21. Dezember 2021
